Roivant Sciences (ROIV) Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old Mar 15, 2023 07:46AM
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old Mar 15, 2023 07:45AM
Roivant Sciences (ROIV) and Pfizer (PFE) Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases Dec 1, 2022 08:05AM
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases Dec 1, 2022 08:00AM
Roivant (ROIV) and Pfizer (PFE) Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus Jun 28, 2022 06:00AM


Jun 28, 2022 06:00AM Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
May 24, 2022 06:00AM FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years
May 16, 2022 07:00AM Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)
Mar 25, 2022 08:01AM Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting